Find a study
Match me to a study72 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Fatty liver disease (NASH/MASH)
π 89bio Clinical Study Site Β· Birmingham, AL Β· +39 more US sites Β· Get directions β
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.
- Fatty liver disease (NASH/MASH)
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
π΅ May compensateπ GSK Investigational Site Β· Arcadia, CA Β· +39 more US sites Β· Get directions β
This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
- Fatty liver disease (NASH/MASH)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
π΅ May compensateπ 89bio Clinical Study Site Β· Birmingham, AL Β· +39 more US sites Β· Get directions β
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
- Fatty liver disease (NASH/MASH)
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
π΅ May compensateπ Akero Clinical Study Site Β· Birmingham, AL Β· +39 more US sites Β· Get directions β
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
- Fatty liver disease (NASH/MASH)
LIVERAGEβ’ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
π΅ May compensateπ The Institute for Liver Health II DBA Arizona Clinical Trials Β· Peoria, AZ Β· +39 more US sites Β· Get directions β
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study.
- Fatty liver disease (NASH/MASH)
π Arizona Liver Health Β· Chandler, AZ Β· +39 more US sites Β· Get directions β
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH).
- Fatty liver disease (NASH/MASH)
π Akero Clinical Study Site Β· Birmingham, AL Β· +39 more US sites Β· Get directions β
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
- Fatty liver disease (NASH/MASH)
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
π΅ May compensateπ GSK Investigational Site Β· Arcadia, CA Β· +39 more US sites Β· Get directions β
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
- Fatty liver disease (NASH/MASH)
LIVERAGEβ’: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
π΅ May compensateπ University of Alabama at Birmingham Β· Birmingham, AL Β· +39 more US sites Β· Get directions β
This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function.
- Fatty liver disease (NASH/MASH)
π Arizona Liver Health Β· Chandler, AZ Β· +39 more US sites Β· Get directions β
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.
- Fatty liver disease (NASH/MASH)
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
π΅ May compensateπ Arizona Liver Health - Chandler Β· Chandler, AZ Β· +34 more US sites Β· Get directions β
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
- Fatty liver disease (NASH/MASH)
π Arizona Liver Health - Chandler Β· Chandler, AZ Β· +30 more US sites Β· Get directions β
Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also asse
- Obesity / overweightFatty liver disease (NASH/MASH)
Fibrosis Lessens After Metabolic Surgery
π΅ May compensateπ Banner Health Center Β· Phoenix, AZ Β· +3 more US sites Β· Get directions β
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.
- Fatty liver disease (NASH/MASH)
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
π΅ May compensateπ University of California San Diego Β· La Jolla, CA Β· +15 more US sites Β· Get directions β
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH.
- Fatty liver disease (NASH/MASH)
Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
π΅ May compensateπ Weill Cornell Medicine Β· New York, NY Β· Get directions β
This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterranean diet and 30 minutes of exercise on at least 5 days/week) on the degree of fat in the liver as measured by magnetic resonance imaging.
- Fatty liver disease (NASH/MASH)
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
π΅ May compensateπ Arizona Liver Health Β· Chandler, AZ Β· +6 more US sites Β· Get directions β
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NASβ₯4 \& Fβ₯2 from those without.
- Fatty liver disease (NASH/MASH)
π Centre de recherche du CHUS Β· Sherbrooke, Quebec Β· Get directions β
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis. MASLD results from fat being disproportionately deposited in the liver.
- Fatty liver disease (NASH/MASH)
π London Health Sciences Centre/Western University Β· London, Ontario Β· Get directions β
Non-alcoholic fatty liver disease is becoming increasingly common in Canada and throughout the world. Fatty liver can increase the risks of perioperative complications for those who need liver surgery.
- Fatty liver disease (NASH/MASH)
π University of San Fransisco Β· San Francisco, CA Β· +3 more US sites Β· Get directions β
Participants meeting study entry criteria are randomized with equal probability to one of two study groups: (1) Lifestyle modification or (2) Vertical Sleeve Gastrectomy (VSG) with Iifestyle modification, followed for 12 months. The primary goal for the trial is to determine if the investigators can recruit, randomize, and retain participants to perform invasive and non-invasive measurements of NASH and fibrosis, deliver lifestyle modification and demonstrate the safety of VSG.
- Fatty liver disease (NASH/MASH)
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
π΅ May compensateπ Clinical Pharmacology of Miami Β· Miami, FL Β· +3 more US sites Β· Get directions β
The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.
- Fatty liver disease (NASH/MASH)
π Arizona Liver Health Β· Chandler, AZ Β· Get directions β
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B).
- Fatty liver disease (NASH/MASH)
π GSK Investigational Site Β· Rialto, CA Β· +2 more US sites Β· Get directions β
This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.
- Fatty liver disease (NASH/MASH)
Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD
π΅ May compensateπ OrsoBio Research Site Β· Guadalajara, Jalisco Β· Get directions β
This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.
- Fatty liver disease (NASH/MASH)
π Centre Hospitalier Universitaire de la Guyane Β· Cayenne, Β· Get directions β
Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity. Analysis of PNPLA3 polymorphisms in an overseas territories population of MASLD would be interesting to describe their profile susceptibility to develop Metabolic dysfunction associated steatohepatitis (MASH).
- Obesity / overweightFatty liver disease (NASH/MASH)
π Brigham and Women's Hospital Β· Boston, MA Β· +1 more US site Β· Get directions β
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease.
- Fatty liver disease (NASH/MASH)
π Centre Hospitalier de l'UniversitΓ© de MontrΓ©al Β· Montreal, Quebec Β· Get directions β
Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).
- Obesity / overweightFatty liver disease (NASH/MASH)
π Brigham and Women's Hospital Β· Boston, MA Β· +1 more US site Β· Get directions β
The goal of this observation study is to assess whether endoscopic ultrasound shear wave elastography (EUS-SWE) may be a useful tool for liver fibrosis screening in patients with elevated body mass index and non alcoholic fatty liver disease as compared to other non-invasive screening modalities, which have traditionally had less accurate results in this population. The main questions it aims to answer are: * Determine accuracy of EUS-SWE for liver fibrosis screening compared to other non-invasive scoring systems, such as the FIB-4 score and Fibroscan in patients with elevated body mass index * Establish optimal stiffness (kPa) cutoffs for liver fibrosis grading for EUS-SWE for this patient population in reference to the gold standard liver biopsy, as no standard cutoffs currently exist.
- Type 2 diabetesFatty liver disease (NASH/MASH)
π Texas Diabetes Institute - University Health System Β· San Antonio, TX Β· +1 more US site Β· Get directions β
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
- Fatty liver disease (NASH/MASH)
Endoscopic Ultrasound Shear Wave Elastography Study
π΅ May compensateπ Brigham and Women's Hospital Β· Boston, MA Β· +1 more US site Β· Get directions β
This study shall be a prospective, multicenter, single arm, consecutive, interventional study conducted in a post-market setting using commercially available devices. Consecutive, eligible patients with clinical suspicion of MASLD or MASH reporting for an endoscopic ultrasound and liver biopsy for evaluation of fibrosis will be enrolled.
- Fatty liver disease (NASH/MASH)
π University of California San Francisco Β· San Francisco, CA Β· +1 more US site Β· Get directions β
The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time. NAFLD happens when fat builds up in the liver which can cause damage to the liver such as inflammation or scarring.
- Fatty liver disease (NASH/MASH)
π Magnetic Resonance Research Center (MRRC) Β· New Haven, CT Β· +1 more US site Β· Get directions β
The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have a family history of type 2 diabetes. Hepatic mitochondrial oxidation will be assesses using a 3 hour triple tracer study (D7 glucose, 3-13C lactate and 13C4 beta-hydroxybutyrate).
- Fatty liver disease (NASH/MASH)
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
π΅ May compensateπ Mayo Clinic in Rochester Β· Rochester, MN Β· +1 more US site Β· Get directions β
Nonalcoholic Steatohepatitis (NASH) is a condition with increased amount of fat, inflammation and scarring in the liver. In compensated cirrhosis, the liver is coping with this damage and maintaining its important functions.
- Fatty liver disease (NASH/MASH)
π Yale New Haven Health Β· New Haven, CT Β· +1 more US site Β· Get directions β
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment for NASH, which was recently renamed metabolic associated steatohepatitis (MASH), involves lifestyle interventions to promote weight loss and to treat comorbidities such as hypertension, hyperlipidemia, and diabetes mellitus.
- Fatty liver disease (NASH/MASH)
π Cincinnati Children's Hospital Medical Center Β· Cincinnati, OH Β· Get directions β
A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities.
- Obesity / overweightFatty liver disease (NASH/MASH)
π University of California San Diego Β· La Jolla, CA Β· Get directions β
This is a feasibility study that will collect data to assess the potential effect of nutritional intervention. This prospective single-site trial will enroll adult patients with liver diseases such as metabolic-dysfunction associated steatotic liver disease (MASLD), metabolic-dysfunction associated steatohepatitis (MASH), cirrhosis and/or hepatocellular carcinoma (HCC).
- Obesity / overweightFatty liver disease (NASH/MASH)
π Mayo Clinic in Arizona Β· Scottsdale, AZ Β· Get directions β
This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin resistance.
- Fatty liver disease (NASH/MASH)
π Massachusetts General Hospital Β· Boston, MA Β· Get directions β
NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD.
- Fatty liver disease (NASH/MASH)
π Yale New Haven Hospital Β· New Haven, CT Β· Get directions β
The main aim of the study is to discover the mechanisms underlying the pathophysiology of NAFLD in obese youth.
- Obesity / overweightFatty liver disease (NASH/MASH)
π NIDDK, Phoenix Β· Phoenix, AZ Β· Get directions β
Background: Children s weight has increased sharply in recent years. This may put them at higher risk for health problems.
β Study care freeLearn more β - Obesity / overweightFatty liver disease (NASH/MASH)Heart / cardiovascular disease
π University of Missouri-Columbia Β· Columbia, MO Β· Get directions β
The purpose of this research study is to validate (check the accuracy of) laboratory assays, intravenous catheter insertion, and equipment or devices and their reproducibility, which is necessary to perform high quality research on chronic diseases, nutrition, and metabolism (the process by which a substance is handled in the body) at the University of Missouri. As technology changes and uses new testing methods, it is necessary to compare results from old tests, equipment and devices and new tests, equipment, or devices and the reproducibility of these measurements to make sure the results are accurate.
- Obesity / overweightFatty liver disease (NASH/MASH)
π University of Missouri School of Medicine Β· Columbia, MO Β· Get directions β
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.
- Fatty liver disease (NASH/MASH)
π Institut sur la nutrition et les aliments fonctionnels (INAF) Β· QuΓ©bec, Quebec Β· Get directions β
This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota among both men and women with MASLD.
- Obesity / overweightFatty liver disease (NASH/MASH)
π University of Missouri School of Medicine Β· Columbia, MO Β· Get directions β
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.
- Obesity / overweightFatty liver disease (NASH/MASH)
π University at Buffalo, Buffalo General Medical Center Β· Buffalo, NY Β· Get directions β
The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.
- Obesity / overweightFatty liver disease (NASH/MASH)
π Univeristy of Colorado Anschutz Medical Campus Β· Aurora, CO Β· Get directions β
Participants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo "fake supplement" for 2 months to see if the participants who get the protein supplement have less fat in the liver compared to participants who were in the placebo group. After the 2 month intervention, all participants can continue the study and will all receive the protein supplement for an additional 10-months.
- Obesity / overweightFatty liver disease (NASH/MASH)
π Stanford University Β· Stanford, CA Β· Get directions β
This 12-week controlled diet and weight intervention study seeks to define the molecular pathways that link excess body weight to the development of insulin resistance (IR). Blood, adipose and stool are sampled at three timepoints; baseline, peak weight (4 weeks) and post weight loss to monitor changes in cellular processes.
- Obesity / overweightFatty liver disease (NASH/MASH)
Human Models of Selective Insulin Resistance: Alpelisib, Part I
π΅ May compensateπ Columbia University Irving Medical Center Β· New York, NY Β· Get directions β
The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin.
- Obesity / overweightFatty liver disease (NASH/MASH)
Effect of Insulin Lowering on Lipogenesis
π΅ May compensateπ Columbia University Irving Medical Center Β· New York, NY Β· Get directions β
The goal of this clinical trial is to compare a one-week course of diazoxide (2 mg/kg per dose x 14 doses) and placebo in people with obesity and insulin resistance (IR) with metabolic dysfunction-associated steatotic liver disease (MASLD). The main question it aims to answer are how mitigation of compensatory hyperinsulinemia with diazoxide affects hepatic de novo lipogenesis, a major contributor to MASLD pathophysiology.
- Type 2 diabetesFatty liver disease (NASH/MASH)
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
π΅ May compensateπ University of Florida Β· Gainesville, FL Β· Get directions β
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
- Type 2 diabetesFatty liver disease (NASH/MASH)
π Centricity Research Toronto LMC. Β· Toronto, Β· Get directions β
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose.
- Fatty liver disease (NASH/MASH)
π Penn State Hershey Medical Center Β· Hershey, PA Β· Get directions β
There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD.
- Fatty liver disease (NASH/MASH)
Evaluating the Pharmacokinetics and Safety of Miricorilant
π΅ May compensateπ Site# 433 Β· San Antonio, TX Β· Get directions β
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Fatty liver disease (NASH/MASH)
π University of Washington Β· Seattle, WA Β· Get directions β
The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD).
- Fatty liver disease (NASH/MASH)
π Virginia Commonwealth University Β· Richmond, VA Β· Get directions β
In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic Resonance Imaging (MRI) and laboratory results.
- Fatty liver disease (NASH/MASH)
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
π΅ May compensateπ Ann & Robert H Lurie Children's Hospital of Chicago Β· Chicago, IL Β· Get directions β
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Fatty liver disease (NASH/MASH)
π Dana Farber Cancer Institute Β· Boston, MA Β· Get directions β
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.
β Study care freeLearn more β - Fatty liver disease (NASH/MASH)
π Harry S. Truman Memorial, Columbia, MO Β· Columbia, MO Β· Get directions β
Nonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver disease, which is rapidly becoming a worldwide public health problem. It is more common in the military and Veteran population compared to the general US population.
- Fatty liver disease (NASH/MASH)
π McMaster University Medical Center Β· Hamilton, Ontario Β· Get directions β
The FIND study will look at the effect of a nutritional mixed fibre supplement, oligofructose and inulin (OF+INU), on children with non-alcoholic fatty liver disease. In this randomized, double- blind controlled trial, subjects will be given a supplement, in the form of oral pills, and will have bloodwork performed, their diets analyzed, and liver fat measured at several timepoints.
- Fatty liver disease (NASH/MASH)
π Henry Ford Health System Β· Detroit, MI Β· Get directions β
The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile.
- Fatty liver disease (NASH/MASH)
π Massachusetts General Hospital Β· Boston, MA Β· Get directions β
Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite this, the treatment options remain limited.
- Showing the first 60 of 72. Add filters or a location to narrow down.